These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32517194)

  • 1. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
    Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers.
    Salvati A; Giurato G; Lamberti J; Terenzi I; Crescenzo L; Melone V; Palo L; Giordano A; Sabbatino F; Roscigno G; Quintavalle C; Condorelli G; Rizzo F; Tarallo R; Nassa G; Weisz A
    Mol Cancer; 2024 Aug; 23(1):160. PubMed ID: 39113071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals.
    Szostakowska M; Trębińska-Stryjewska A; Grzybowska EA; Fabisiewicz A
    Breast Cancer Res Treat; 2019 Feb; 173(3):489-497. PubMed ID: 30382472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
    Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
    Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
    Jacquemetton J; Kassem L; Poulard C; Dahmani A; De Plater L; Montaudon E; Sourd L; Morisset L; El Botty R; Chateau-Joubert S; Vacher S; Bièche I; Treilleux I; Trédan O; Marangoni E; Le Romancer M
    Breast Cancer Res; 2021 May; 23(1):57. PubMed ID: 34020697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
    Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
    AlFakeeh A; Brezden-Masley C
    Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.
    Jia Y; Song Y; Dong G; Hao C; Zhao W; Li S; Tong Z
    Sci Rep; 2019 Sep; 9(1):12939. PubMed ID: 31506496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.
    Bieche I; Parfait B; Le Doussal V; Olivi M; Rio MC; Lidereau R; Vidaud M
    Cancer Res; 2001 Feb; 61(4):1652-8. PubMed ID: 11245479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment.
    Li Y; Kong X; Xuan L; Wang Z; Huang YH
    J Cell Mol Med; 2021 Nov; 25(22):10327-10348. PubMed ID: 34651424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
    Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery.
    Suba Z
    Recent Pat Anticancer Drug Discov; 2016; 11(3):254-66. PubMed ID: 27087654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
    Burstein HJ; Lacchetti C; Griggs JJ
    J Oncol Pract; 2019 Feb; 15(2):106-107. PubMed ID: 30523754
    [No Abstract]   [Full Text] [Related]  

  • 15. Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
    Giuliano M; Schifp R; Osborne CK; Trivedi MV
    Breast; 2011 Oct; 20 Suppl 3():S42-9. PubMed ID: 22015292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
    Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
    J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer.
    Kulkoyluoglu E; Madak-Erdogan Z
    Steroids; 2016 Oct; 114():41-47. PubMed ID: 27394959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of endocrine therapy resistance in breast cancer.
    Rasha F; Sharma M; Pruitt K
    Mol Cell Endocrinol; 2021 Jul; 532():111322. PubMed ID: 34000350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment algorithms for hormone receptor-positive advanced breast cancer: going forward in endocrine therapy—overcoming resistance and introducing new agents.
    Johnston SR; Schiavon G
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK; Marquez-Garban DC; Pietras RJ
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.